Using NF-κκB as a molecular target for theranostics in radiation oncology research. (March 2012)

• Record Type: Journal Article
• Authors: Liu, Yu-Chang; Chiang, I-Tsang; Hsu, Fei-Ting; Hwang, Jeng-Jong
• Is Part Of: Expert review of molecular diagnostics. Volume 12:Number 2(2012)
• Page Start: 139
• Page End: 146
• Publication Date: 2012-03
• Subjects: chemoresistance -- IKK inhibitor -- molecular targeting -- nanoparticle -- NF-κκB -- radioresistance -- sorafenib; Molecular diagnosis -- Periodicals; 616.0758205
• DOI: 10.1586/erm.12.2
• Languages: English
• ISSNs: 1473-7159

Abstract

Resistance of cancer cells to chemotherapy and/or radiotherapy is a major challenge to current anticancer treatment. The NF-κκB signaling pathway plays an important role in tumor development and progression, and results in unsatisfactory treatment outcome. Inhibition of the NF-κκB signaling cascade may sensitize the resistant cancer cells to chemotherapy and/or radiotherapy. Here, the correlation of NF-κκB molecules with carcinogenesis and tumor progression, along with its significance in clinical practice, is reviewed. The potential clinical application of NF-κκB and its associated molecules as diagnostic and therapeutic targets is also discussed.